Smoke-free England

Mary Glindon Excerpts

Tuesday 29th March 2022 Westminster Hall

[Sir Charles Walker (Broxbourne) (Con)]

I beg to move,

That this House has considered progress towards a smoke-free England.

I will start by reading a couple of paragraphs from an excellent Government document published in July 2017, entitled “Towards a smoke-free generation”. I will not detain the Chair too long, but there are a few sentences that I want to read into the record. The document says:

“Over 200 deaths every day are still caused by smoking…Smoking rates have remained stubbornly higher amongst those in our society who already suffer from poorer health and other disadvantages. Smoking rates are almost three times higher amongst the lowest earners, compared to the highest earners…Smoking accounts for approximately half the difference in life expectancy between the richest and poorest in society. This injustice in the variation in smoking prevalence can be seen across England; from places where adult smoking is as low as 5% to others where smoking remains above 25%. The prevalence remains even higher in people with mental health conditions, where more than 40% of adults with a serious mental illness smoke. We want to address this. Our vision is nothing less than to create a smokefree generation…the government will provide leadership and guidance on the most effective interventions.”

There we have it: a bold statement of intent. So what does a smoke-free 2030 look like? First, it is not smoke-free. When we talk about a smoke-free 2030, we are actually talking about 5% or less of the adult population smoking—that is recognised by The Lancet. Currently, more than 14% of the adult population smoke, and it could actually be higher than 14%, because lockdown may have increased the prevalence of smoking as people turned to cigarettes as a way of releasing and relieving stress. Cancer Research UK is not optimistic about the 2030 date, which will not come as a surprise to anyone here. Its best guess is that 2037 is when we will achieve 5% or less, and I am afraid the general view is that 2037 now looks optimistic.

To put it in context, what is 200 deaths a day? That is 75,000 deaths a year and, on top of that, 500,000 admissions to hospital every year for smoking-related illnesses. Over 10 years, 750,000 people will die from smoking. That is approximately the population of Birmingham every 10 years, and 5 million people will be admitted to hospital.

The Government touch on the huge disparities in smoking between richer and less well-off areas. In some of the most deprived wards in seaside towns in the north-west, smoking rates are above 22%. In the leafy parts of Surrey, they are less than 5%—in essence, parts of Surrey have achieved smoke-free status. What does 22% versus 5% look like? That translates into about an eight-year differential in life expectancy. Of course, not all that eight-year differential will be linked to smoking but, as the Government identified in their report in 2017, about 50%—four years—of that differential will be linked to the fact that more people smoke in more deprived areas than wealthier ones.

Look, the Government have made great strides. I will not be churlish with the Minister—I would not be churlish with her, because she is a very nice woman and she is very committed to this cause, which is more important than being nice.

I understand that a pack of cigarettes now costs more than £10, although that is not something I have bought for 17 years. Some might be pushing £14, so this is becoming an expensive habit. Even at that price, 14% or more of the population are smoking. We are down to some really tough nuts to crack, if we want to reach that 5%. I remind the Government of the part of the report entitled, “Backing evidence-based innovation”:

“Despite the availability of effective medicines and treatments to support quit attempts, the majority of smokers choose to quit unassisted, by going ‘cold turkey’. This has proved to be the least effective method…The best thing a smoker can do for their health is to quit smoking. However, the evidence is increasingly clear that e-cigarettes are significantly less harmful to health than smoking tobacco. The Government will seek to support consumers in stopping smoking and adopting the use of less harmful nicotine products.”

[Mary Glindon (North Tyneside) (Lab)]

I congratulate the hon. Member on this Adjournment debate. He may know that I have never smoked, but I am a strong advocate of vaping. Does he agree that, if the Government are serious about reducing smoking prevalence, they must ensure that medical professionals have access to the latest evidence on e-cigarettes and are encouraged to signpost patients to appropriate guidance about harm reduction, as well as information about how to switch successfully, if they cannot quit?

[Sir Charles Walker]

Of course, I agree with and endorse what the hon. Lady said—on this occasion, let me call her my hon. Friend—because what we are talking about today is harm reduction.

Let me read two more sentences, from page 15 of the report, which I am sure will be of interest to the hon. Lady:

“The Government will therefore continue to evaluate critically the evidence on nicotine-delivery products, providing clear communication about what is known and unknown about the short and long-term risks of using different products relative to smoking and the absolute risk to children, non-smokers and bystanders.”

Remember that that was written five years ago, so there has surely been time to do this.

What I do not understand is why the Government are so squeamish when it comes to looking at harm reduction. The hon. Member for North Tyneside talks about vaping, but there are nicotine pouches, “heat not burn” products and something called snus, which I understand is used in parts of the world. Before we cast these alternatives aside, let us remember that they reduce the harm caused to the user. There is nothing more harmful than smoking burnt, lit, combustible tobacco—nothing. Sweden has taken an enlightened approach. It has embraced science and looked at harm reduction. Smoking rates are now well below 10%, and some independent experts reckon they are nearer 7%. It looks like Sweden is going to be the first country in Europe to meet the magical 4.99% and be a smoke-free European country.

I am concerned that we are not going at this problem as hard as we should as a nation, but there is hope, which I am sure the Minister will refer to in her speech. There is the independent review of smoke-free 2030 policies, led by Mr Javed Khan OBE. The review offers reasons for optimism. In its objectives it states:

“The review will make a set of focused policy and regulatory recommendations in 2 areas, and will consider…the most impactful interventions to reduce the uptake of smoking, particularly among young people.”

It will also consider

“the top interventions to support smoking cessation, particularly in deprived areas of England where there are significant health disparities”.

That sounds like a call to arms. On outputs, the review says:

“The review will provide a far-reaching report focused on the key policy and regulatory recommendations that give the government the best chance of achieving the Smokefree 2030 ambition and addressing the health disparities associated with smoking.”

Can I make a plea to the Minister and her Department? This issue is harm reduction. It is about reducing the 75,000 deaths a year. It is about reducing the 500,000 people who go into hospital. It is not about banishing nicotine.

In a perfect world, nobody would even chew nicotine gum, but the fact is that they do. We do not live in a perfect world. People become addicted to nicotine, and it becomes part of their day. It is far better to consume it in a way that offers a much lesser chance of either shortening someone’s life or putting them in hospital. Let us use the regulatory and tax environments to differentiate harms, so that the highest harm is combustible tobacco and we can gradate the level of harm going down. We can use the tax system to signpost people to the least harmful nicotine product.

I would like to conclude by saying one thing. Levelling up has to mean reducing the disparities in people’s life expectancy. One of the greatest disparities is in those who suffer from a diagnosis of psychosis/schizophrenia. By the Government’s own reckoning, 40% of people with the diagnosis—possibly more—smoke. I know about this because I have been deeply involved in the issue of mental health since I entered Parliament 17 years ago. Smoking is often linked to the treatments used to help people with psychosis/schizophrenia—sadly often still called the chemical cosh. The treatments tend to enhance appetite, so people experience massive weight gain. They also tend to depress the person in receipt of the medications, which drives them to smoking. On average, if someone has a diagnosis of psychosis/schizophrenia, their life expectancy is reduced by 15 years—the Government say in their document that it is between 10 and 20 years. This is a real issue for so many people. This is not a “nice to have” harm reduction; it is an absolute necessity. I thank you, Ms Rees, and the Minister for allowing me to make the case for harm reduction today.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health and Social Care (Maggie Throup)]

First, I thank my hon. Friend the Member for Broxbourne (Sir Charles Walker) for calling this important debate. I am grateful to him for his contribution and I am grateful to other Members who share the Government’s ambition for Britain to be smoke-free by 2030. My hon. Friend is correct when he says that that means 5% of people smoking, but it would still be a great achievement to get from where we are now to just 5%. The UK is a world-leader on tobacco control and we now have one of the lowest smoking rates in the world. According to my records, only 13.5% of people in the UK smoke, but that percentage is still too high. As he stated so passionately, the Government know there is still so much more to do.

We know that there are still around 6 million smokers in England and that smoking remains the single biggest cause of preventable mortality; two out of three long-term smokers will die from smoking. We also know that smoking is one of the largest drivers of health disparities and that the burden of tobacco harms is not shared equally. Smoking rates are far higher in poorer areas of the country, as my hon. Friend said, and among lower socioeconomic groups. We can see smoking rates of 23% in more deprived areas, compared with rates of 8% in wealthier ones. In addition, one in 10 pregnant women still smoke, increasing the risk of health problems for their babies. Smoking prevalence among people with long-term mental health conditions is also far too high, at over 25%.

My hon. Friend the Member for Windsor (Adam Afriyie) raised the issue of smoking during pregnancy. The decline there has not fallen in line with other groups, so we know that more needs to be done. We continue to explore options to support smoking cessation in pregnant women; those options will be set out in our tobacco control plan and they are also part of our NHS long-term plan. We know that it is not just the woman who needs support; it is her partner as well. We must continue to help those groups in all the ways we can.

What are we doing? In 2019 the Government set the bold ambition for England to be smoke-free by 2030. To support that, we have been building on the successes of our current tobacco control plan, and later this year we will publish a new plan with an even sharper focus on tackling health disparities. The new plan will set out a comprehensive package of new policy proposals and regulatory change. To help push those ambitions forward, the Government have commissioned an independent review of our tobacco control policies, led by Javed Khan, the former CEO of Barnado’s. The review will assess the most impactful interventions to help us achieve our goal of being smoke-free by 2030. I know that Javed Khan has some really ambitious ideas that I am sure my hon. Friend the Member for Broxbourne will welcome.

More needs to be done to prevent young people from taking up smoking and to protect our future generations from its devastating harms. More also needs to be done to support current smokers to quit, especially in deprived communities and among the priority groups. Smoking, and the grip it has on our society, must become a thing of the past. I am confident that the Khan review will give us the focus and political support to do so. I encourage all hon. Members to contribute to the review so that we can hear as wide a range of views as possible. We are open to bold new ideas about how to reach our smoke-free ambitions. Hon. Members have talked about the role of reduced-risk products. The Government are supportive of smokers using less harmful nicotine delivery systems to quit or switch away from the most harmful form—combustible tobacco.

[Mary Glindon]

This week is the beginning of VApril, which is a campaign run by the industry to support smokers who are looking to quit. Would the Minister support efforts to encourage adult smokers to quit by speaking with local authority stop smoking services, this month in particular, and highlight the role of e-cigarettes in reducing harm?

[Maggie Throup]

The hon. Lady—I will call her my hon. Friend—speaks passionately about vaping, and we have had those conversations before. We know and acknowledge that reduced-risk products are not risk-free, but vaping is a way to help people stop smoking and it has been proven to be effective. We must continue to ensure that the products do not appeal to young people and non-smokers—that is really important. However, we need to get the message out that vaping is an effective way to stop smoking. Balanced and proportionate regulation is required as we shift to different products. We have an innovative and varied nicotine market in the UK, as has been mentioned; vapes are by far the most popular alternative source of nicotine, but there are also patches, gums and, more recently, nicotine pouches.

We want to see more smokers using vapes to quit, which I know is in line with the wishes of the hon. Member for North Tyneside (Mary Glindon). She mentioned earlier the possibility of vaping and e-cigarettes being available on prescription, and the Secretary of State has spoken of his desire to see those products routinely prescribed by the NHS. That is something that we need to move forward with. My hon. Friend the Member for Windsor raised the important issue of the perception of vaping and how it has changed. That is something I will take away and consider.

Health Inequalities: Office for Health Improvement and Disparities

Mary Glindon Excerpts

Wednesday 26th January 2022 Westminster Hall

[Mary Glindon (North Tyneside) (Lab)]

It is an honour to serve under your chairmanship, Mr Twigg. I congratulate my hon. Friend the Member for Bootle (Peter Dowd) on an excellent, well-researched speech and on securing this important debate.

Before turning to the exact subject of the debate, as vice-chair of the all-party parliamentary group for vaping, I want to reflect on the role of the predecessor body of the Office for Health Improvement and Disparities. Public Health England sought to be a practical institution, with evidence and pragmatism at the heart of its approach to public life. I want to pay particular attention to its work on tobacco harm reduction, which I have witnessed not only as a member of the APPG but personally. Since 2015, across seven evidence reviews, PHE reports on the role that e-cigarettes can play in a healthier society have captured the ethos of the organisation in its entirety.

The first report was a landmark publication for the vaping industry. It concluded—I hope that everyone in this House heeds this fact when reflecting on reducing inequalities born from smoking cigarettes—that vaping is “95% less harmful” than tobacco. In its report, PHE went on to look favourably on e-cigarettes, while others have sought only to fuel misinformation, risking lives by claiming vaping and smoking to be one and the same. They are not. It is because of that evidence-based endorsement of vaping that millions of smokers across England and—dare I say it?—across the world, who have exhausted all other routes trying to quit smoking, have a fighting chance with an incredibly successful product that is helping smokers to quit.

Smoking is perhaps one of the biggest contributors to inequality in our society, causing considerable damage to private and public health, and it has a high impact on physical and mental health. It is an expensive and addictive habit, particularly for those most disadvantaged in our society, where smoking prevalence is highest. Vaping is less expensive and is an effective way to stop smoking. It is therefore critical that the Office for Health Improvement and Disparities recognises the role of vaping, picks up the torch left by Public Health England and continues to be a stalwart champion of tobacco harm reduction.

This could not be more important as we continue to wait for the Department of Health and Social Care to publish, first, its review of the Tobacco and Related Products Regulations 2016—that review is now eight months late—and secondly, its new tobacco control plan, which is also late and nowhere to be seen. The APPG for vaping’s door is always open to the Minister, and I know that leading bodies such as the UK Vaping Industry Association would welcome the chance to work with Government to secure a future in which the health benefits of switching from smoking to vaping are fully realised. The UKVIA has industry-led solutions to many of the remaining concerns that prevent people from finally making the switch to vaping. Those solutions include the guidance it produced on introducing restrictions on packaging and branding. I support that paper, and can share it with the Minister if she wishes.

The UK is seen by many across the world as a world leader in tobacco harm reduction, with countries, smokers and vapers looking to the UK for guidance in this space. That reputation should not be compromised by the loss of institutional knowledge during the transfer of resource from Public Health England to OHID, and it should not come at the cost of a Government Department delaying publications once again. If the Government are serious about levelling up and wish to support endeavours to improve people’s lives, they must ensure that OHID adopts the same evidence-based approach as its predecessor to finding solutions for life-debilitating problems.

I once again express my gratitude to my hon. Friend the Member for Bootle for having secured this debate. I hope that in responding, the Minister can provide clarity about the timeline for responding to the TRPR review and for the publication of the new tobacco control plan. I also hope that she agrees that the OHID must remain independent, with its institutional knowledge protected.

Medical Cannabis: Alleviation of Health Conditions

Mary Glindon Excerpts

Thursday 4th November 2021 Commons Chamber

[Mary Glindon (North Tyneside) (Lab)]

It is an honour to follow the hon. Member for Edinburgh West (Christine Jardine). I congratulate the hon. Member for Inverclyde (Ronnie Cowan) on securing this debate, which, as everyone has said, is yet another debate on the same issue. Three years on from when we had such hope, it is disappointing that we find ourselves still here.

I am going to speak yet again about one of my constituents, a very brave and formidable woman who is known to many in the House, because she has been courageously campaigning for the medical use of cannabis by highlighting the problems she has faced in recent years to access the drug Bedrocan. Lara Smith is a wife and the mother of three children. She was a paediatric nurse and a county fencing coach before her health deteriorated because of cervical and lumbar spondylosis. For over 20 years, she has had 35 different medications, as well as a number of operations for her condition. Unfortunately, she has been left with permanent nerve damage, limited mobility and a constant, annoying and debilitating tremor in her right hand. Her quality of life has been completely impaired. That is not just because of her medical condition, but because of the awful side effects of the drugs she has been prescribed over all those years. This has meant that Lara was not able to be the full-time mother that she wanted to be to her daughters and son.

Fortunately, Lara’s pain management consultant in the north-east prescribed Bedrocan, and the transformation was such that she was able to come off all the other medications. Her young family said that they felt they had their mam back. The downside was that for a time, Lara could access the drug only by travelling to a Dutch pharmacy to collect it on a private prescription. I have said it before, so I will not go into it again, but she made that arduous journey every three months, bearing in mind the pain she was in. She had to notify full details of her prescription and her travel to Border Force each time. The costs of the medication and travel were very expensive for her family, but they thought that the sacrifice was worthwhile, because of the difference the drug made to Lara.

A couple of years ago, I was successful in raising the issue at Prime Minister’s questions. I received a response from the appropriate Minister at the time, who said that

“there should be no barriers to patients getting access to the appropriately prescribed medicine. The Department of Health and Social Care…has been working closely with suppliers and NHS procurement pharmacists to ensure that prescribed CBPM are available when needed.”

If only that were the case.

Fortunately, Lara no longer has to travel to Holland for her drugs—they are prescribed on a private prescription—but her consultant has unfortunately been unsuccessful in obtaining an individual funding request for her, which is a great disappointment to us all. That is because unfortunately the Northumbria trust—it is a well-respected and well-known trust in many ways, and I always support our trust for a lot of the good things it does, but I am rather frustrated in this instance—followed guidelines that do not advocate the use of cannabinoids, citing a lack of evidence for effective pain relief, because of the difference in the trials put forward to prescribe the drugs, and we have already heard about that issue. On that score, there has been no progress. Perhaps the biggest irony of all is that the trust advocates and allows the prescription of synthetic cannabinoids. For Lara’s drug, a synthetic cannabinoid is £588 a month and unfortunately leaves her quite ill; she pays £100 less for her private prescription. Such a state of affairs seems ludicrous.

There is nothing much I can add to what has been said today. All the speeches are always passionate, and Members speak with such knowledge on the subject—knowledge that has had to be acquired over all the years there has been the fight to win the case. I know that the new Minister, having worked with her on all-party parliamentary groups, is compassionate and knowledgeable, so we put great hope in her that we will see some progress after today’s debate and the other debates that have gone before. I wish her the best of luck in taking this forward, and I am sure she knows we are all behind her. We hope there will be change for the adults and children whose quality of life needs to be improved and can easily be improved if some changes are made in law.

Smoking Cessation: Prescription of E-cigarettes

Mary Glindon Excerpts

Monday 1st November 2021 Commons Chamber

[Maggie Throup]

My hon. Friend is right that e-cigarettes are just a gateway to stopping smoking completely. That is the ultimate goal. We want to ensure that people go from smoking to e-cigarettes, and then to no smoking at all.

[Mary Glindon (North Tyneside) (Lab)]

COP9 is due to start next week and, as yet, the Government have not announced their delegation. Will the Minister therefore please tell us who the delegates might be and what their approach will be to COP9, given that the World Health Organisation is completely against vaping?

[Maggie Throup]

There will be officials at COP9. It is a very important meeting. The UK’s approach to e-cigarettes has been and always will be pragmatic and evidence-based. I am sure that will be the message they put forward at COP9.

Dame Carol Black’s Independent Review of Drugs Report

Mary Glindon Excerpts

Wednesday 27th October 2021 Westminster Hall

[Mary Glindon (North Tyneside) (Lab)]

It is an honour to serve under your chairmanship, Ms Fovargue. I congratulate my hon. Friend the Member for Liverpool, Walton (Dan Carden) on securing the debate, and on the way that he spoke with great knowledge and passion. I declare my interest as co-chair of the drugs, alcohol and justice cross-party parliamentary group. In that capacity it was my privilege to introduce Professor Dame Carol Black to address our group the week after she published her report. My co-chair, Lord Ramsbotham, has repeatedly asked in the other place when the Government will establish the long-awaited royal commission on the criminal justice system. I hope the Minister may have some news on that for us.

Dame Carol’s report recommended earlier interventions for offenders to divert them away from the criminal justice system, particularly prison. Providing people with pathways into treatment, rather than into the criminal justice system, seems an eminently sensible approach because, as Dame Carol observed:

“Rarely are prison sentences a restorative experience.”

Over a third of prison places in England and Wales are taken up because of drug-related offences.

I pay tribute to the pioneering work of the late Ron Hogg, who, as Durham’s police and crime commissioner, introduced a successful checkpoint scheme. We have since heard of other excellent diversion schemes, such as those developed in the West Midlands and in Thames Valley—we desperately need more like them. I am glad that Ron’s successor, Joy Allen, along with Dorset PCC Dave Sidwick, is leading the PCCs’ work on addiction. I am sure the Minister will join me in welcoming their dedication to helping people towards a safer and healthier future.

Dame Carol understands that addiction is a chronic health condition, arising as people try to cope with trauma and other issues. Her report rightly condemned the current situation as intolerable. Drug-related deaths are at record levels, the impact of drug-related harms in many places is getting worse and the worst affected areas are those with greatest deprivation. I am sad to say that the highest rate of drug misuse deaths in 2020 was once again in the north-east, which according to the ONS has had the highest rate of drug misuse for the past eight years, with a significantly higher rate than other regions of England and over three times the rate of London.

We know drug treatment has seen years of disinvestment. Some services have seen budgets nearly halved as funding has been redirected to other local government priorities. There has been an absence of political leadership and financial commitment to address the concerns of the sector, with very clear and obvious consequences. A range of treatment providers welcome Dame Carol’s review, fully endorse her recommendations for a whole system approach and told our group they were keen to seize this unique opportunity to rebuild and renew our treatment and recovery system. Jon Murray, an executive director at With You told us:

“This review represents a potentially defining moment in the course of drug treatment in the UK.”

Yasmin Batliwala, chair of the Westminster Drug Project said:

“This report has the potential to be a game changer!”

Karen Tyrell, executive director at Humankind added:

“Dame Carol Black has provided the map needed to get the sector back on course and we urge the government to employ their moral compass, invest accordingly and help us turn this ship around.”

For far too long, piecemeal investment through path- finders and pilot schemes failed to provide the stability for providers to develop the long-term plans, and recruit and retain the high-quality staff, that are needed to meet the ambitions laid out in the review. As recommended, ringfenced funding is essential for the sector to build and maintain a resilient support system for the hundreds of thousands of people who so desperately need and deserve those services. I sincerely hope that the Government will act on all of Dame Carol’s recommendations.

Tobacco Control Plan

Mary Glindon Excerpts

Thursday 10th June 2021 Westminster Hall

[Mary Glindon (North Tyneside) (Lab)]

It is an honour to serve under your chairmanship, Mrs Miller. I thank my hon. Friend the Member for City of Durham (Mary Kelly Foy) for having secured this important debate and speaking so eloquently, especially as the Department of Health and Social Care is looking to publish a new tobacco control plan later this year. The forthcoming plan is an enormous opportunity for the Government to cement the UK as a global leader in tobacco harm reduction. Having left the European Union, the Government must—alongside the post-implementation review of the tobacco and related products regulations—set a clear direction for reducing smoking prevalence and improving public health.

However, if the Government are to achieve their ambition for a smoke-free society by 2030, their forthcoming tobacco control plan must champion the less harmful alternatives to combustible tobacco. In particular, a significant and growing body of scientific evidence shows vaping to be the most effective alternative for adult smokers looking to quit smoking. In their blueprint for better regulation, the UK Vaping Industry Association made a series of recommendations to the Department of Health for consideration when reviewing the tobacco and related products regulations—a process that is already underway. These recommendations, many of which I support, can also be applied to the Government’s tobacco control plan.

The first recommendation involves effectively tackling the increasing levels of misinformation, as well as the increasing misperception of the relative harm of e-cigarettes versus combustible tobacco. Action on Smoking and Health data suggests that millions of smokers—more than half of the 6.9 million remaining in the UK—could now be dissuaded from exploring switching to e-cigarettes because of incorrect views or confusion about the harm of e-cigarettes. To combat increasing misinformation, the UKVIA recommends that the Department of Health launch an effective communication strategy. This should include the introduction of approved health claims and switching messages that can be displayed on vape device and e-liquid packaging alongside nicotine health warnings, a proposal similar to those explored by the Governments of Canada and New Zealand.

In addition, it is important that medical professionals at local stop smoking services are sufficiently supported, with clinicians signposted to the latest clinical guidance and evidence on e-cigarettes. An evidence-based approach to smoking cessation must be adopted consistently by local stop smoking services to support patients in their harm reduction journey. This is critical, considering the upcoming trials in NHS A&E departments. The forthcoming tobacco control plan should also make provisions for a review of the regulation of nicotine in e-cigarettes, to better understand the role nicotine plays in allowing e-cigarettes to be a satisfying alternative for adult smokers wishing to make the switch away from smoking. For them to compete with combustible cigarettes and provide a satisfactory alternative for those looking to switch, they must provide a comparably satisfying nicotine experience. It is the toxic by-products of combustion, not the nicotine, that are responsible for smoking-related death and disease.

Understanding the alternatives to combustible cigarettes and making a clear distinction between smoking and vaping is critical to our smoke-free ambitions and changing misconceptions. Our all-party parliamentary group for vaping made several recommendations in our report on vaping in workplaces and public places. These are endorsed by the UKVIA and, if implemented, would support adult smokers in their transition to less harmful alternatives and give those who have already made the switch the best chance of sticking at it. I can provide the Minister with a copy of that report, if she so wishes. My late husband Ray is an example of such a switcher: having smoked from the age of nine with a couple of interludes, he made the switch to vaping several years ago, and was never separated from what he called his “pipe”. I might add that he did not die of a smoking-related illness.

Finally, I turn to another opportunity to enact the meaningful regulatory change to support smoking cessation. The Government are currently considering the submissions made to the consultation on the review of the Tobacco and Related Products Regulations 2016. Like many others, I eagerly await the publication of the Department’s response, which has already been delayed from May 2021 until later this year. It is hoped that the Department of Health and Social Care will continue to take an evidence-based approach to the regulations and listen to the experts. The TRPR review can help shape the UK’s approach to tobacco harm reduction considerably and can significantly support the next tobacco control plan. I look forward to the Government’s response to the tobacco and related products regulations review and the publication of the tobacco control plan. I hope that they make the most of these unique opportunities to support adult smokers in their transition to a less harmful alternative.

UK Rare Diseases Framework

Mary Glindon Excerpts

Wednesday 24th March 2021 Westminster Hall

[Mary Glindon (North Tyneside) (Lab) [V]]

It is a great honour to serve under your chairmanship, Mrs Miller. I congratulate my hon. Friend the Member for Blaydon (Liz Twist) on securing the debate and on her excellent opening speech. The rare diseases framework is welcome, but in order to deliver on the vision it is important to reflect on the experiences of those with rare diseases over the past year.

I chair the all-party parliamentary group on muscular dystrophy, and last month our meeting brought together people living with muscle-wasting conditions, leading health professionals and charities representing relatives to discuss the impact of covid-19. It came after a month-long survey conducted by Muscular Dystrophy UK to assess the impact of covid-19 on people living with muscle-wasting conditions and their families and the effect on accessing healthcare services. There were over 400 survey responses and they were very concerning. The comments made at our APPG meeting backed up many of the survey’s findings.

We heard that the delivery of standard care had been put on hold and essential services were interrupted, and that it was proving very difficult to regain muscle strength after losing six months to a year of physiotherapy. Some had experienced diagnostic tests being put on hold as resources were diverted because of the pandemic and a number of clinical trials were also halted. Worryingly, the physical and mental impact of shielding has left many people reluctant to go out even to hospitals when restrictions are relaxed.

Our APPG also considered what might happen when restrictions are relaxed and we return to some kind of normal life. Infrastructure challenges for service provision still remain, and there is concern about if and when staff and resources redirected to covid-19 will return to neuromuscular services. Virtual clinics have had a positive impact and there are benefits to be taken forward of continuing these for some people, especially taking into account issues such as long travel times. However, not everything can be assessed or picked up virtually. Routine face-to-face appointments are still critical.

Members of the APPG are always grateful for the support of our secretariat Muscular Dystrophy UK, medical professionals and those with muscle-wasting conditions. On their behalf, I ask the Minister to outline how the action plans for the framework will learn from patient and health professional experiences during the pandemic, and will also shape the priorities for accessing essential specialist care and mental health support.

Covid-19 Update

Mary Glindon Excerpts

Thursday 26th November 2020 Commons Chamber

[Matt Hancock]

We look as much as we can at taking the impacts into account. For instance, the mental health of people under lockdown is of course more challenged than in normal circumstances. We balance that against the impact of covid both directly and in filling up the hospitals on the healthcare that we all get for all the other conditions that exist. It is a difficult balance to strike. On the particular impact on mental health, which my hon. Friend raised, the Royal College of Psychiatrists has done very interesting work to understand the nuanced balance between the impact of covid on people’s mental health and the impact of lockdown. Both are significant and I commend its work to him.

[Mary Glindon (North Tyneside) (Lab) [V]]

It is devastating that after all its efforts, the north-east will be in tier 3. Across the whole country, obesity remains a serious factor in covid-19. Yesterday, the all-party group on obesity launched its report to build on the Government’s obesity strategy. Will the Minister meet officers of the group to discuss the report’s recommendations and work with us to ensure a focus on the prevention and treatment of obesity in the fight against covid-19?

[Matt Hancock]

Yes. the hon. Member and I share an enthusiasm for this agenda with the Prime Minister, who is a personal convert to the need to tackle obesity. In fact, this crisis shows how important it is, because people who are obese are more likely to have a more serious impact from covid, if they catch it.

Oral Answers to Questions

Mary Glindon Excerpts

Tuesday 23rd June 2020 Commons Chamber

[Andrew Gwynne (Denton and Reddish) (Lab)]

What steps he is taking to tackle regional variations in the restoration of cancer services after the covid-19 outbreak.

[Mary Glindon (North Tyneside) (Lab)]

What steps his Department is taking to enable the resumption of cancer treatments delayed as a result of the covid-19 outbreak.

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

Essential and urgent cancer treatment has continued throughout the pandemic and cancer specialists, as always, are discussing the best treatment options with their patients. We are working to ensure that referrals, diagnostics and cancer treatment are back at pre-pandemic levels across the whole of England as soon as possible. Due to covid-19, the 21 cancer alliances in England have established hubs to ensure dedicated cancer care away from hospitals dealing with the virus. From the end of April, local systems and cancer alliances have continued to identify ring-fenced diagnostic and surgical capacity for cancer in line with issued guidance. Regional cancer senior responsible officers must now provide assurance that these arrangements are in place to help minimal regional variation.

--- Later in debate ---

[Jo Churchill]

I regularly engage with cancer charities and would be delighted to look at them to see where we are making good headway and where, perhaps, we could have discussions about other things that need to be targeted. While I have the hon. Gentleman on the screen, I would also like to highlight the fact that the Greater Manchester cancer alliance has led the way in its response to this pandemic. It was one of the first to establish a surgical hub model to ensure that cancer surgery was able to continue and that the local cancer system as a whole responded well. The alliance has also been looking to accelerate the rapid diagnostic centre to help promote diagnostics, so I thank everyone for that.

[Mary Glindon [V]]

As the Minister knows, being diagnosed with cancer is devastating, and one of the most important things to get patients through this difficult time is for them to be able to focus on their treatment. What message does the Minister have to comfort those people who are worried and stressed because they still cannot access the treatment they need because of covid-19?

[Jo Churchill]

I would say that, as soon as people notice any signs that might worry them, they should seek help. We have worked at pace to ensure that services have been resumed and are able to deliver for patients. Ensuring both early diagnosis and that patients can access the treatment that they need swiftly is our key ambition. We know that, following the guidance that has been delivered, we are achieving that throughout the system. Covid-19 has upended all our lives, and some decisions have been made to ensure the safety of patients, but we are now firmly back on track and will ensure that patients get the care they need.

The National Health Service

Mary Glindon Excerpts

Wednesday 23rd October 2019 Commons Chamber

[Mary Glindon (North Tyneside) (Lab)]

It is an honour to follow the hon. Member for Dudley South (Mike Wood). I think the whole House wishes him all the best of health in the future, having recovered from that terrible illness.

I congratulate all the staff at Northumbria Healthcare NHS Foundation Trust because, for the second time in a row, they have received a rating of outstanding from the CQC. I have to declare an interest, as members of my family work for the trust, but it was great news to know that the organisation is providing outstanding services to my constituents, despite all the cuts that have been imposed over the years.

I must turn from a message of congratulations to the trust to complaining to the Government about an issue that people have already highlighted: the problem being faced by all those who desperately need access to medical cannabis, including my constituent, Lara Smith, who is known to people in here for courageously highlighting the problems she has faced in recent years in accessing the medicine Bedrocan.

Lara was a paediatric nurse and a county fencing coach before her health deteriorated because of cervical and lumber spondylosis. She has been on 35 different medications and had several operations for her condition. Unfortunately, she has been left with permanent nerve damage, limited mobility and a constant tremor in her right hand. Her quality of life has been impaired, not just because of her medical condition, but, particularly, because of the drugs she was prescribed for it.

Lara’s pain management consultant prescribed her Bedrocan and the transformation was such that she was able to come off all her other medications, but the downside is that she can access the drug only by travelling to a Dutch pharmacy to collect it. That is an expensive, arduous journey by ferry, which she makes every three months and has done so for four years. She always notifies the UK Border Agency of all the details it needs to know of her prescription and travel details, but, sadly, and most embarrassingly for her, on her last trip she was pulled aside by the agency, which wanted to check her medication. Of course, she was mortified and she worries it might happen again.

Lara’s message to the Minister is that she is more than fed up with having to travel 300 miles to a Dutch pharmacy to get her medication. Can the Minister give her any reassurance that things will change soon, as he promised when he met patients’ families from the End Our Pain campaign in March this year? Access to medical cannabis was legalised last November, so why has nothing happened to help patients since then?

I also wish to thank Dr Azzabi and the all the staff at the northern cancer care centre who have looked after my husband Ray since he was diagnosed with incurable prostate cancer four years ago. I give special thanks to the staff on ward 36, who are now seeing him through his chemotherapy. Ray was very lucky because when he was diagnosed he received instant treatment, which was a massive blessing for us. However, other cancer patients are not so lucky, and once they are diagnosed—a terrible blow to the family—as we know from the targets, treatment is now taking longer and longer. It is hard enough to be diagnosed with cancer, but knowing you have to wait for your treatment is unbearable.

Our staff in the health service are under pressure and services are lacking. Our precious health service deserves more. I hope that the Government will heed all the messages today and have taken note.